Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

E-Mindfulness Approaches for Living After Breast Cancer

NCT06748222 · View on ClinicalTrials.gov ↗

Study Summary

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.

Conditions Studied

Interventions

  • BEHAVIORAL Mindfulness (MAPs) Live Online
  • BEHAVIORAL Mindfulness (MAPs) Digital App
  • BEHAVIORAL Meditation Only Control Group

Study Locations (20)

California

  • Kaiser Permanente-Deer Valley Medical Center — Antioch
  • AIS Cancer Center at San Joaquin Community Hospital — Bakersfield
  • Marshall Cancer Center — Cameron Park
  • Enloe Medical Center — Chico
  • UC Irvine Health Cancer Center-Newport — Costa Mesa
  • Kaiser Permanente Dublin — Dublin
  • Kaiser Permanente-Fremont — Fremont
  • Washington Hospital — Fremont
  • Kaiser Permanente Fresno Orchard Plaza — Fresno
  • Kaiser Permanente-Fresno — Fresno
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
  • Fremont - Rideout Cancer Center — Marysville
  • Kaiser Permanente- Modesto MOB II — Modesto
  • Kaiser Permanente-Modesto — Modesto
  • Kaiser Permanente-Oakland — Oakland
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange
  • Eisenhower Medical Center — Rancho Mirage
  • Kaiser Permanente- Marshall Medical Offices — Redwood City

Arizona

  • Mayo Clinic Hospital in Arizona — Phoenix

Arkansas

  • Mercy Hospital Fort Smith — Fort Smith

Trial Details

FieldValue
Enrollment Target 402 participants
Start Date 2025-06-12
Est. Completion 2030-02-28
Phase Phase 3

Sponsor

NRG Oncology

162 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06748222

The ClinicalTrials.gov registry entry for NCT06748222 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 162 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions — of which Mindfulness (MAPs) Live Online is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06748222 reports 20 study locations spanning 3 distinct geographic areas — top geographies include California, Arizona, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06748222 about?

NCT06748222 is a clinical study titled "E-Mindfulness Approaches for Living After Breast Cancer". NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wil...

What is the current status of trial NCT06748222?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2025-06-12. Estimated completion is 2030-02-28.

What conditions does trial NCT06748222 study?

This clinical trial studies the following conditions: Breast Cancer, Depression. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06748222?

The interventions under investigation include: Mindfulness (MAPs) Live Online (BEHAVIORAL), Mindfulness (MAPs) Digital App (BEHAVIORAL), Meditation Only Control Group (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06748222?

This trial is sponsored by NRG Oncology, which has 162 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06748222 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial